FR2471190A1 - THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR - Google Patents

THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR Download PDF

Info

Publication number
FR2471190A1
FR2471190A1 FR7930380A FR7930380A FR2471190A1 FR 2471190 A1 FR2471190 A1 FR 2471190A1 FR 7930380 A FR7930380 A FR 7930380A FR 7930380 A FR7930380 A FR 7930380A FR 2471190 A1 FR2471190 A1 FR 2471190A1
Authority
FR
France
Prior art keywords
weight
parts
antitussive
cough
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7930380A
Other languages
French (fr)
Other versions
FR2471190B1 (en
Inventor
Jacques Bodin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Pharm SA Laboratoires
Original Assignee
Human Pharm SA Laboratoires
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Pharm SA Laboratoires filed Critical Human Pharm SA Laboratoires
Priority to FR7930380A priority Critical patent/FR2471190A1/en
Priority to BE2/58895A priority patent/BE886573A/en
Priority to IT8068888A priority patent/IT8068888A0/en
Priority to GB8039718A priority patent/GB2064959B/en
Publication of FR2471190A1 publication Critical patent/FR2471190A1/en
Application granted granted Critical
Publication of FR2471190B1 publication Critical patent/FR2471190B1/fr
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/714Aconitum (monkshood)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENTION A TRAIT A UNE COMPOSITION THERAPEUTIQUE SANS SUCRE, UTILE DANS LE TRAITEMENT DE LA TOUX, ET RENFERMANT: A.4,5 A 8,5PARTIES EN POIDS D'UN COMPOSE CHOISI PARMI L'ETHYLMORPHINE ET SES SELS; B.10 A 70PARTIES EN POIDS DE TEINTURE D'ACONIT; C.1 A 3PARTIES EN POIDS D'UN COMPOSE CHOISI PARMI LA CHLORPHENIRAMINE ET SES SELS; ET D.10 A 30PARTIES EN POIDS DE GLYCEROGAIACOL. CETTE COMPOSITION FORMULEE AVEC UN AGENT EPAISSISSANT DU TYPE ETHER DE CELLULOSE ET DE L'EAU EST ADMINISTRABLE PAR VOIE ORALE.THE PRESENT INVENTION RELATES TO A THERAPEUTIC COMPOSITION WITHOUT SUGAR, USEFUL IN THE TREATMENT OF Cough, AND CONTAINING: A 4.5 TO 8.5 PARTS BY WEIGHT OF A COMPOUND CHOSEN FROM ETHYLMORPHINE AND ITS SALTS; B.10 TO 70PARTMENTS BY WEIGHT OF ACONITE TINCTURE; C.1 HAS 3PARTS BY WEIGHT OF A COMPOUND CHOSEN FROM CHLORPHENIRAMINE AND ITS SALTS; AND D.10 TO 30 PARTS BY WEIGHT OF GLYCEROGAIACOL. THIS COMPOSITION FORMULATED WITH A THICKENING AGENT OF THE ETHER TYPE OF CELLULOSE AND WATER IS ADMINISTRABLE ORAL.

Description

24711 9024711 90

Composition thérapeutique, utile dans le traitement de la toux, comprenant un moyen antitussif, un moyen antispasmodique, un moyen  Therapeutic composition, useful in the treatment of cough, comprising antitussive means, antispasmodic means, means

antihistaminique et un moyen expectorant.  antihistamine and an expectorant means.

La présenté invention a trait, en tant que produit industriel nouveau et utile en thérapeutique dans le traitement de  The present invention relates, as a new industrial product and useful in therapeutics in the treatment of

la toux, à une composition comprenant en association un moyen anti-  coughing, to a composition comprising in combination an ant

tussif, un moyen antispasmodique, un moyen antihistaminique et un moyen expectorant. On sait que dans le passé on a commercialisé des spécialités pour le traitement de la toux comprenant en association  tussif, antispasmodic means, antihistamine and expectorant means. It is known that in the past there have been commercialized specialties for the treatment of cough comprising in association

une ou plusieurs substances antitussives, antispasmodiques, anti-  one or more antitussive substances, antispasmodic, ant

histaminiques, expectorantes et/ou antiseptiques. Parmi les substances antitussives qui ont été utilisées on peut mentionner la codéine, la Néthyl-3,4-dihydroxynoréphédrine (ou dioxyéthédrine) et la teinture  histamine, expectorant and / or antiseptic. Of the antitussive substances that have been used, mention may be made of codeine, N-3,4-dihydroxynorephedrine (or dioxyethedrine) and dyeing.

d'aconit, cette dernière ayant des propriétés antitussives et anti-  aconite, the latter having antitussive and anti-

spasmodiques. Parmi les substances antihistaminiques, on peut citer  spasmodic. Among the antihistamine substances, mention may be made of

la prométhazine et parmi les substances expectorantes et/ou anti-  promethazine and among expectorant and / or

septiques, l'hydroxyquinoléine, le sulfogalacol. De telles spécialités présentent l'inconvénient de contenir du sucre, car conditionnées  septic drugs, hydroxyquinoline, sulfogalacol. Such specialties have the disadvantage of containing sugar, because packaged

sous forme de sirop.in the form of syrup.

Pour traiter la toux de patients (notamment les diabétiques) ne devant pas ou ne voulant pas prendre de sucre, des  To treat the coughing of patients (especially diabetics) not having or wanting to take sugar,

solutions techniques différentes de la solution sirop rappelée ci-  technical solutions different from the syrup solution mentioned

dessus et n'impliquant pas l'utilisation de sucre ont été préconisées, en particulier celles qui consistent à administrer un principe actif  above and not involving the use of sugar have been advocated, in particular those of administering an active ingredient

antitussif tel que l'orthoformiate d'éthyle, la N-(p-acétyloxime-  antitussive such as ethyl orthoformate, N- (p-acetyloxime)

phénoxy-acétyl)-morpholine, la N-(p-acétyloxime-phénoxy-acétyl)-pipé-  phenoxy-acetyl) -morpholine, N- (p-acetyloxime-phenoxy-acetyl) -piperazine

ridine et les analogues de ces deux dernières du type p-oximephénoxy-  ridine and the analogs of the latter two of the p-oximephenox-

alkylamide décrits dans les brevets français n0 69.39954 et  alkylamide described in French Patent Nos. 69.39954 and

72.36165, sous forme de comprimés, gélules ou suppositoires.  72.36165, in the form of tablets, capsules or suppositories.

Selon l'invention, on préconise une autre solution technique qui consiste à administrer une association particulière  According to the invention, it is recommended another technical solution which consists in administering a particular association

de moyens antitussif, antispasmodique, antihistaminique et expectorant.  antitussive, antispasmodic, antihistaminic and expectorant means.

Un des buts de l'invention est de proposer une associa-  One of the aims of the invention is to propose an association

tion synergétique pour le traitement de la toux.  synergetic treatment for the treatment of cough.

Un autre des buts de l'invention est de proposer une association de moyens antitussif, antispasmodique, antihistaminique et expectorant, sous forme de solution buvable pour le traitement de la toux, ladite solution buvable étant sirupeuse,c'est-à-dire  Another object of the invention is to propose a combination of antitussive, antispasmodic, antihistaminic and expectorant means, in the form of an oral solution for the treatment of cough, said oral solution being syrupy, that is to say

ayant l'aspect d'un sirop, mais ne comportant pas de sucre.  having the appearance of a syrup, but not containing sugar.

Un autre des buts de l'invention est de préparer une associa-  Another object of the invention is to prepare an associa-

tion exempte de sodium.sodium free.

La composition selon l'invention est caractérisée en ce qu'el- le renverme, en association avec un excipient physiologiquement  The composition according to the invention is characterized in that it reverses, in association with a physiologically excipient.

acceptable,acceptable,

a) 4,5 à 8,5 parties en poids d'un composé choisi parmi l'éthylmorphine et ses sels; b) 10 à 70 parties en poids de teinture d'aconit; c) I à 3 parties en poids d'un composé choisi parmi la chlorphéniramine et ses sels; et  a) 4.5 to 8.5 parts by weight of a compound selected from ethylmorphine and its salts; b) 10 to 70 parts by weight of aconite dye; c) I to 3 parts by weight of a compound selected from chlorpheniramine and its salts; and

d) 10 à 30 parties en poids de glycérogalacol.  d) 10 to 30 parts by weight of glycerogalacol.

La substance a) agit en tant que produit antitussif. Parmi les sels utilisables on peut mentionner le chlorhydrate,lecamphosulfonate,  The substance a) acts as an antitussive product. Among the salts that may be used, mention may be made of the hydrochloride, lecamphosulphonate,

ou le méthyliodure, les sels préférés étant le chlorhydrate (codé-  or methyliodide, the preferred salts being the hydrochloride (coded as

thyline) et le camphosulfonate.thyline) and camphosulphonate.

La substance b) agit comme antitussif et antispasmodique.Elle  Substance b) acts as antitussive and antispasmodic.It

est préparée selon le procédé d'extraction décrit dans la pharmacopée.  is prepared according to the extraction method described in the pharmacopoeia.

La substance c), c'est-à-dire la chlorphéniramine ou 2-/-4-  Substance (c), that is, chlorpheniramine or 2 - / - 4-

chloro- v-(2-diméthylaminoéthyl)-benzyl/-pyridine et ses sels, in-  chlorov (2-dimethylaminoethyl) benzyl / pyridine and its salts,

tervient en tant qu'agent antihistaminique.Le sel préféré selon l'in-  as an antihistamine agent.The preferred salt according to

vention est le maleate.vention is maleate.

La substance d) également connue sous les nomenclatures de 3-(ométhoxyphénoxy)-1,2-propanediol et de gaïacol glycéryl éther agit  Substance d) also known under the nomenclature of 3- (omethoxyphenoxy) -1,2-propanediol and guaiacol glyceryl ether acts

en tant que substance expectorante.as an expectorant substance.

De façon avantageuse on préparera une composition aqueuse buvable en associant les substances a)-d) à un agent épaississant e) choisi parmi l'ensemble des éthers de cellulose tels que,notamment,  Advantageously, an aqueous drinkable composition will be prepared by combining the substances a) -d) with a thickening agent e) chosen from the group of cellulose ethers such as, in particular,

les méthylcellulose,éthylcellulose, hydroxyéthyl-cellulose, hydroxy-  methylcellulose, ethylcellulose, hydroxyethyl cellulose, hydroxyl

propyl-méthylcellulose,carboxyméthylcellulose, et de l'eau déminéra-  propyl methylcellulose, carboxymethylcellulose, and demineral water.

lisée ou distillée.La composition selon l'invention comprendra alors: a) 4,5 à 8,5 parties en poids d'un composé choisi parmi l'éthylmorphine et ses sels; b) 10 à 70 parties en poids de teinture d'aconit; c) 1 à 3 parties en poids d'un composé choisi parmi la chlorphéniramine et ses sels; d) 10 à 30 parties en poids de glycérogalacol; et  The composition of the invention will then comprise: a) 4.5 to 8.5 parts by weight of a compound selected from ethylmorphine and its salts; b) 10 to 70 parts by weight of aconite dye; c) 1 to 3 parts by weight of a compound selected from chlorpheniramine and its salts; d) 10 to 30 parts by weight of glycerogalacol; and

e) 30 à 70 parties en poids d'éther de cellulose.  e) 30 to 70 parts by weight of cellulose ether.

Le moyen e) appartenant à la famille des éthers de cellulose permet d'obtenir un produit final sirupeux et transparent analogue aux sirops mais exempt de sucre. Les substances e) préférées sont l'hydroxyéthylcellulose, la méthylcellulose et leurs mélanges. Le meilleur mode de mise en oeuvre de l'inaeti.on consiste à administrer une composition aqueuse buvable (A):C; la formulation suivante:  The means e) belonging to the family of cellulose ethers makes it possible to obtain a syrupy and transparent final product similar to syrups but without sugar. The preferred substances e) are hydroxyethylcellulose, methylcellulose and mixtures thereof. The best mode of implementation of inaeti.on is to administer an aqueous drinkable composition (A): C; the following wording:

COMPOSITION ACOMPOSITION A

(i) codéthyline (chlorhydrate d!éthy1marphine)i 45 à 85 mg (ii) teinture d'aconit 100 à 700 mg (iii} maléate de chlorphéniramine 10 a 30 mg (iv) glycérogalacol 100 à 300 mg (v) éther de cellulose 300 a 700 mg (vi) eau déminéralisée qsp 100 ml Les essais cliniques ont mis en évidence les propriétéY synergétiques de la composition A et en particulier des compositions des exemples 1 à 4, ci-après. On a en effet constaté chez l'homme que la composition A était, vis-à-vis de la toux, 30 à 100 % plus  (i) codethylamine (ethylamine hydrochloride) 45 to 85 mg (ii) tincture of aconite 100 to 700 mg (iii) chlorpheniramine maleate 10 to 30 mg (iv) glycerogalacol 100 to 300 mg (v) cellulose ether 300 to 700 mg (vi) demineralised water qs 100 ml Clinical trials have demonstrated the synergistic properties of composition A and in particular the compositions of Examples 1 to 4, hereinafter. that the composition A was, with respect to the cough, 30 to 100% more

efficace que la codéthyline seule, l'aasociation codéthyline -  effective than codethyline alone, codethylamine aasociation -

teinture d'aconit et l'association codéthyline - teinture d'aconit -  tincture of aconite and the combination of codethylamine and aconite tincture

maléate de chlorphéniramine.chlorpheniramine maleate.

La posologie recommandée est de trois prises par jour,  The recommended dosage is three times daily,

de 10 à 15 ml chacune,de composition A pendant 3 jours.  10 to 15 ml each, composition A for 3 days.

Les exemples qui suivent, nullement limitatifs,ont été  The following examples, which are in no way limiting, have been

donnés à titre d'illustration.given as an illustration.

Exemple 1Example 1

Selon la formulation de la composition A on prépare une composition aqueuse buvable ayant la formulation suivante: 30. codéthyline 65 mg teinture d'aconit 500 mg maléate de chlorphéniramine 20 mg glycérogalacol 300 mg hydroxyéthylcellulose 500 mg 35. eau déminéralisée qsp 100 ml  According to the formulation of the composition A, an aqueous drinkable composition is prepared having the following formulation: 30. codethyline 65 mg tincture of aconite 500 mg chlorpheniramine maleate 20 mg glycerogalacol 300 mg hydroxyethylcellulose 500 mg 35. demineralized water qs 100 ml

Le cas échéant, on peut introduire dans cette formu-  Where appropriate, it may be introduced in this formu-

lation un colorant et un arSme.a dye and arsen.

Exemple 2Example 2

On prépare comme à l'exemple 1, une composition aqueuse buvable, en remplaçant les 500 mg d'hydroxyéthyl-  As in Example 1, an aqueous drinkable composition is prepared, replacing the 500 mg of hydroxyethyl

cellulose de l'exemple 1, par un mélange de 200 mg d'hydroxy-  cellulose of Example 1, with a mixture of 200 mg of hydroxypropyl

éthylcellulose et de 300 mg de méthylcellulose.  ethylcellulose and 300 mg of methylcellulose.

Exemple 3Example 3

On prépare comme à l'exemple 1, une composition aqueuse buvable ayant la formulation suivante: codéthyline 50 mg teinture d'aconit 520 mg maléate de chlorphéniramine 25 mg glycérogaiacol 300 mg 15. méthylcellulose 600 mg eau déminéralisée qsp 100 ml  A drinkable aqueous composition having the following formulation is prepared as in Example 1: codethylamine 50 mg tincture of aconite 520 mg maleate of chlorpheniramine 25 mg glycerogaiacol 300 mg 15. methylcellulose 600 mg demineralized water qs 100 ml

Exemple 4Example 4

aqueuse buvable On prépare comme à l'exemple 1, ayant la formulation suivante:  aqueous drinkable is prepared as in Example 1, having the following formulation:

camphosulfonate d'éthyl-ethyl camphorsulphonate

morphine teinture d'aconit maléate de chlorphéniramine glycérogalacol: hydroxyéthylcellulose eau déminéralisée une composition mg 500 mg mg mg 500 mg  morphine tincture of aconite chlorpheniramine maleate glycerogalacol: hydroxyethylcellulose demineralized water a composition mg 500 mg mg mg 500 mg

qsp 100 ml.qsp 100 ml.

Claims (4)

REVENDICATIONS -CLAIMS - 1. Composition thérapeutique utile dans le traitement de la toux, comprenant un moyen antitussif, un moyen antispasmodique, un moyen antihistaminique et un moyen expectorant, caractérisée en ce qu'elle renferme, en association avec un excipient physiologique- ment acceptable: a) 4,5 à 8,5 parties en poids d'un composé choisi parmi l'éthylmorphine et ses sels; b) 10 à 70 parties en poids de teinture d'aconit; c) 1 à 3 parties en poids d'un composé choisi parmi la chlorphéniramine et ses sels; et  1. A therapeutic composition useful in the treatment of cough, comprising an antitussive means, an antispasmodic means, an antihistaminic means and an expectorant means, characterized in that it contains, in association with a physiologically acceptable excipient: a) 4 5 to 8.5 parts by weight of a compound selected from ethylmorphine and its salts; b) 10 to 70 parts by weight of aconite dye; c) 1 to 3 parts by weight of a compound selected from chlorpheniramine and its salts; and d) 10 à 30 parties en poids de glycérogalacol.  d) 10 to 30 parts by weight of glycerogalacol. 2. Composition thérapeutique selon la revendication 1, caractérisée en ce qu'elle renferme en outre e) 30 à 70 parties en poids d'agent épaississant  2. Therapeutic composition according to claim 1, characterized in that it additionally contains e) 30 to 70 parts by weight of thickening agent. choisi parmi l'ensemble constitué par les éthers de cellulose.  selected from the group consisting of cellulose ethers. 3. Composition thérapeutique utile dans le traitement de la toux, destinée à être administrée sous forme de composition  3. Therapeutic composition useful in the treatment of cough, to be administered as a composition aqueuse buvable, comprenant un moyen antitussif, un hoyen antispas-  aqueous solution, comprising antitussive means, a antispeed hoyen modique, un moyen antihistaminique et un moyen expectorant, caracté-  a moderate antihistamine and expectorant risée en ce qu'elle renferme, en association avec un excipient physiologiquement acceptable:  inasmuch as it contains, in association with a physiologically acceptable excipient: (i) 45 à 85 mg d'un composé choisi parmi l'éthyl-  (i) 45 to 85 mg of a compound selected from ethyl morphine et ses sels, (ii) 100 à 700 mg de teinture d'aconit, (iii) 10 à 30 mg de maléate de chlorphéniramine, (iv) 100 à 300 mg deglycérogalacol, (v) 300 à 700 mg d'éther de cellulose, et  morphine and its salts, (ii) 100 to 700 mg of aconite tincture, (iii) 10 to 30 mg of chlorpheniramine maleate, (iv) 100 to 300 mg glycerogalacol, (v) 300 to 700 mg of cellulose, and (vi) de l'eau en quantité suffisante pour 100 ml.  (vi) water in sufficient quantity per 100 ml. 4- Composition selon la revendication 3, caractérisée en ce qu'elle renferme: (i) 60 mg de chlorhydrate d'éthylmorphine, (ii) 500 mg de teinture d'aconit, (iii) 20 mg de maléate de chlorphéniramine, (iv) 300 mg de glycérogaïacol, (v) 500 mg d'éther de celluloses et  4- Composition according to claim 3, characterized in that it contains: (i) 60 mg of ethylmorphine hydrochloride, (ii) 500 mg of aconite tincture, (iii) 20 mg of chlorpheniramine maleate, (iv) ) 300 mg of glycerogaiacol, (v) 500 mg of cellulose ether and (vi) de l'eau en quantité suffisante pour 100 ml.  (vi) water in sufficient quantity per 100 ml.
FR7930380A 1979-12-11 1979-12-11 THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR Granted FR2471190A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR7930380A FR2471190A1 (en) 1979-12-11 1979-12-11 THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR
BE2/58895A BE886573A (en) 1979-12-11 1980-12-10 THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF Cough COMPRISING AN ANTI-CUSHIONING MEANS, AN ANTISPASMODIC MEANS AND AN EXPECTORING MEANS
IT8068888A IT8068888A0 (en) 1979-12-11 1980-12-11 ANTICOUGH THERAPEUTIC COMPOSITION INCLUDING AN ANTICOUGH AGENT, AN ANTISPASTIC AGENT AND AN EXPECTORANT AGENT
GB8039718A GB2064959B (en) 1979-12-11 1980-12-11 Pharmaceutical anti-tussive composition comprising ethylmorphine aconite tincture and glyceroguaiacol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7930380A FR2471190A1 (en) 1979-12-11 1979-12-11 THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR

Publications (2)

Publication Number Publication Date
FR2471190A1 true FR2471190A1 (en) 1981-06-19
FR2471190B1 FR2471190B1 (en) 1983-04-08

Family

ID=9232652

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7930380A Granted FR2471190A1 (en) 1979-12-11 1979-12-11 THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR

Country Status (4)

Country Link
BE (1) BE886573A (en)
FR (1) FR2471190A1 (en)
GB (1) GB2064959B (en)
IT (1) IT8068888A0 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1465347A (en) * 1973-06-20 1977-02-23 Fisons Corp Composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1465347A (en) * 1973-06-20 1977-02-23 Fisons Corp Composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EXBK/61 *
EXBK/66 *
EXBK/77 *

Also Published As

Publication number Publication date
IT8068888A0 (en) 1980-12-11
GB2064959A (en) 1981-06-24
GB2064959B (en) 1983-12-14
BE886573A (en) 1981-06-10
FR2471190B1 (en) 1983-04-08

Similar Documents

Publication Publication Date Title
TW589174B (en) Agent for treating high-risk impaired glucose tolerance
US6287597B1 (en) Antihistaminic/decongestant compositions
JP4445590B2 (en) Oral liquid composition containing paroxetine-resin
US20040234593A1 (en) Diphenhydramine tannate compositions and methods of use
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
EP0283369B1 (en) Use of Metformin in the preparation of medicaments
KR20100135316A (en) Liquid formulation for deferiprone with palatable taste
JPH04159223A (en) Emetocathartic composition
JP2004534094A (en) Composition effective for hangover and use therefor
JPS6256426A (en) Medicinal composition for treating human malaria
HU225657B1 (en) Process for producing flavano-lignane compositions of improved release and absorption, compositions produced this way find use of them for producing pharmaceutical compositions
FR2482860A1 (en) COMPOSITION AND PREPARATION OF AN ANTIMICROBIAL AGENT
EP1543826B1 (en) Concentrated aqueous solution of ambroxol
RU2261098C2 (en) Mirtazapine-containing orally decomposing composition
WO1999048501A9 (en) Voacamine as anti-malarial agent and anti-malarial agent containing voacamine
FR2912654A1 (en) Medicament composition, useful in treating spasmodic diseases e.g. spastic colitis and dysmenorrhea, comprises phloroglucinol and paracetamol formulated together/separately for combined, simultaneous/separate use of antispasmodic therapy
FR2471190A1 (en) THERAPEUTIC COMPOSITION USEFUL IN THE TREATMENT OF COUGH COMPRISING AN ANTITUSSIVE MEDIUM, AN ANTISPASMODIC MEANS, AN ANTIHISTAMINE MEANS AND A MEDIUM EXPECTOR
US20170020946A1 (en) Analgesic compositions and methods of use
JPH10504279A (en) Pharmaceutical compositions for prevention and / or treatment of viral infections and possibly inflammation and methods of treating them
JP3150642B2 (en) Novel anticonvulsant and anti-inflammatory compositions and methods for their production
AU2003217704A1 (en) Diphenhydramine tannate compositions and methods of use
RU2619736C2 (en) Capsules for complex treatment of urinary system diseases
RU2426531C1 (en) Liquid water pharmaceutical composition of ambroxol and pharmaceutical preparation based on it, intended for treating diseases of respiratory ways with formation of viscous sputum (versions)
BE1007586A3 (en) Pharmaceutical products.
JP2876224B2 (en) New whitening agent

Legal Events

Date Code Title Description
ST Notification of lapse